Influence of GSTM1 and GSTT1 polymorphisms on the survival rate of patients with malignant glioma under perillyl alcohol-based therapy

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1621-1630

  Silva, M M ^a   Da Fonseca, C O ^b   Moura Neto, R ^a   Carvalho, J F ^c   Quirico Santos, T ^b   Carvalho, M G ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c INSTITUTO CARLOS CHAGAS   (Brazil)

Author keywords

Genetic polymorphism; Glioma; Glutathione s transferases; Perillyl alcohol

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; PERILLYL ALCOHOL;

ADULT; AGED; ARTICLE; BRAZILIAN; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CARCINOGENESIS; CASE CONTROL STUDY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; DRUG EFFICACY; ETHNIC GROUP; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; GLIOBLASTOMA; GSTM1 GENE; GSTT1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR LOCALIZATION;

EID: 84878025208     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.May.14.2     Document Type: Article

References (36)

1. Adamson DC, Rasheed BA, McLendon RE and Bigner DD (2010). Central nervous system. Cancer Biomark. 9: 193-210.
2. Belpomme D, Irigaray P, Hardell L, Clapp R, et al. (2007). The multitude and diversity of environmental carcinogens. Environ. Res. 105: 414-429.
3. Cabral REC, Cabral Neto JB and Carvalho MGC (2010). Circulating DNA as a biomarker for early detection of cancer: a brief update with an emphasis on lung cancer. Open Lung Cancer J. 3: 38-44.
4. Carlsten C, Sagoo GS, Frodsham AJ, Burke W, et al. (2008). Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am. J. Epidemiol. 167: 759-774.
5. Carvalho-Silva DR, Santos FR, Rocha J and Pena SD (2001). The phylogeography of Brazilian Y-chromosome lineages. Am. J. Hum. Genet. 68: 281-286.
6. Chaudhary SC, Alam MS, Siddiqui MS and Athar M (2009). Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem. Biol. Interact. 179: 145-153.
7. Chen B, Zhou Y, Yang P and Wu XT (2010). Glutathione S-transferase M1 gene polymorphism and gastric cancer risk: an updated analysis. Arch. Med. Res. 41: 558-566.
8. Coutinho P, Sandim V, Oliveira JA, Alves G, et al. (2010). Lack of association between glutathione S-transferase polymorphisms and primary glioma in a case-control study in Rio de Janeiro. Genet. Mol. Res. 9: 539-544.
9. da Fonseca CO, Linden R, Futuro D, Gattass CR, et al. (2008a). Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch. Immunol. Ther. Exp. 56: 267-276.
10. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, et al. (2008b). Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg. Neurol. 70: 259-266.
11. da Fonseca CO, Teixeira RM, Ramina R, Kovaleski G, et al. (2011). Case of advanced recurrent glioblastoma successfully treated with monoterpene perillyl alcohol by intranasal administration. J. Cancer Ther. 2: 16-21.
12. De Roos AJ, Rothman N, Inskip PD, Linet MS, et al. (2003). Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol. Biomark. Prev. 12: 14-22.
13. Di Pietro G, Magno LA and Rios-Santos F (2010). Glutathione S-transferases: an overview in cancer research. Expert. Opin. Drug Metab. Toxicol. 6: 153-170.
14. Diedrich A, Bock HC, Konig F, Schulz TG, et al. (2006). Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol. Histopathol. 21: 1199-1207.
15. Ebrahimkhani S, Asgharian AM, Nourinaier B, Ebrahimkhani K, et al. (2012). Association of GSTM1, GSTT1, GSTP1 and CYP2E1 single nucleotide polymorphisms with colorectal cancer in Iran. Pathol. Oncol. Res. 18: 651-656.
16. Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, et al. (2002). Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am. J. Epidemiol. 156: 95-109.
17. Ezer R, Alonso M, Pereira E, Kim M, et al. (2002). Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J. Neurooncol. 59: 123-134.
18. Fleischhacker M and Schmidt B (2007). Circulating nucleic acids (CNAs) and cancer - a survey. Biochim. Biophys. Acta 1775: 181-232.
19. Gilbert MR, Gonzalez J, Hunter K, Hess K, et al. (2010). A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncol. 12: 1167-1172.
20. Hayes JD, Flanagan JU and Jowsey IR (2005). Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 45: 51-88.
21. Holstein SA and Hohl RJ (2003). Monoterpene regulation of Ras and Ras-related protein expression. J. Lipid. Res. 44: 1209-1215.
22. Kilburn L, Okcu MF, Wang T, Cao Y, et al. (2010). Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer 116: 2242-2249.
23. Lai R, Crevier L and Thabane L (2005). Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol. Biomark. Prev. 14: 1784-1790.
24. Lee JM, Wu MT, Lee YC, Yang SY, et al. (2005). Association of GSTP1 polymorphism and survival for esophageal cancer. Clin. Cancer Res. 11: 4749-4753.
25. Lo HW and Ali-Osman F (2007). Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. Curr. Opin. Pharmacol. 7: 367-374.
26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114: 97-109.
27. McMartin C, Hutchinson LE, Hyde R and Peters GE (1987). Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. 76: 535-540.
28. Ohgaki H and Kleihues P (2005). Epidemiology and etiology of gliomas. Acta Neuropathol. 109: 93-108.
29. Okcu MF, Selvan M, Wang LE, Stout L, et al. (2004). Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin. Cancer Res. 10: 2618-2625.
30. Pinarbasi H, Silig Y and Gurelik M (2005). Genetic polymorphisms of GSTs and their association with primary brain tumor incidence. Cancer Genet. Cytogenet. 156: 144-149.
31. Qiu LX, Wang K, Lv FF, Chen ZY, et al. (2011). GSTM1 null allele is a risk factor for gastric cancer development in Asians. Cytokine 55: 122-125.
32. Ramnarayan R, Dodd S, Das K, Heidecke V, et al. (2007). Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter. J. Neurol. Sci. 260: 49-56.
33. Rossini A, Rapozo DC, Amorim LM, Macedo JM, et al. (2002). Frequencies of GSTM1, GSTT1, and GSTP1 polymorphisms in a Brazilian population. Genet. Mol. Res. 1: 233-240.
34. Schwartzbaum JA, Ahlbom A, Lonn S, Warholm M, et al. (2007). An international case-control study of glutathione transferase and functionally related polymorphisms and risk of primary adult brain tumors. Cancer Epidemiol. Biomark. Prev. 16: 559-565.
35. Weller M, Stupp R, Hegi M and Wick W (2012). Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18: 40-44.
36. Wiencke JK, Wrensch MR, Miike R, Zuo Z, et al. (1997). Population-based study of glutathione S-transferase mu gene deletion in adult glioma cases and controls. Carcinogenesis 18: 1431-1433.